Dr Fonesca provides his final thoughts recapping data and findings presented at ASH 2023.
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
An update was provided on sonrotoclax, a next-generation BCL2 inhibitor that may exceed venetoclax potency. Early data combining sonrotoclax and dexamethasone shows efficacy in relapsed/refractory multiple myeloma with a favorable toxicity profile. This is an exciting addition given challenges gaining regulatory approval for venetoclax despite its clear value. While this translocation in level 14 imperfectly predicts response, other biomarkers like BCL2 expression levels or BCL2/BCL2L1 ratios could identify responsive patients for BCL2 inhibition. Fonesca hopes sonrotoclax progresses to become the first FDA-approved drug in this class for myeloma.
Looking ahead, 2024 may reveal more around small molecules like BCL2 inhibitors and next-generation cereblon-binding agents. Earlier chimeric antigen receptor T-cell and bispecific antibody data could emerge, potentially transforming outcomes when combined. The recent promising data also warrants follow-up. Fonseca believes properly combining these modalities can achieve high minimal residual disease negativity rates and long-term disease control. While myeloma remains incurable, glimpses of potential cures are being seen that bring hope for the future.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
2 Commerce Drive
Cranbury, NJ 08512